Ensysce Biosciences renews collaboration with Quotient Sciences

Ensysce Biosciences announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product. PF614-MPAR is the Company’s Multi-Pill Abuse Protection unique combination opioid product which shuts off opioid release when too many pills are ingested, thereby stopping deliberate or accidental overdose. The Phase 1b study, PF614-MPAR-102, will evaluate opioid release following administration of PF614-MPAR at doses of 25 mg, 50 mg and 100 mg delivered twice daily for 5 days to verify both overdose protection and effective delivery of oxycodone. The study will apply the Quotient Sciences Translational Pharmaceutics(R) platform to manufacture and test the PF614-MPAR drug product to expedite the clinical study process.